Biocon Ltd. — Interim / Quarterly Report 2025

Aug 8, 2024

==> picture [132 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2024-25/64

August 08, 2024

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol – Biocon

Dear Sir/Madam,

Subject: Press Release on Financial Results for the quarter ended June 30, 2024

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed the press release titled “Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr” pertaining to the un-audited consolidated financial results of Biocon Limited for the quarter ended June 30, 2024.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2024.08.08 19:21:03 +05'30'

---

Mayank Verma Company Secretary & Compliance Officer Membership No.: ACS 18776

Encl: Press Release and Fact Sheet

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

PRESS RELEASE

Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr

Bengaluru, Karnataka, India: August 8, 2024:

Biocon Limited (BSE code: 532523, NSE: BIOCON), an innovation-led global biopharmaceuticals company, today announced its consolidated financial results for the fiscal first quarter ended June 30, 2024.

Q1FY25 | Financial Highlights

Rs 4,567* Crore Rs 1,755 Crore Rs 660 Crore CONSOLIDATED REVENUE EBITDA NET PROFIT 38% 14% Rs 228 Crore EBITDA MARGIN NET PROFIT MARGIN NET R&D INVESTMENT 9% of Revenue Rs 903 Crore CORE EBITDA 26% CORE EBITDA MARGIN

Q1FY25 | Business Segments Revenue

Revenue from Operations : Rs 3,433 Crore

Rs 2,083 Crore BIOSIMILARS: Biocon Biologics Limited

Rs 790 Crore RESEARCH SERVICES: Syngene

Rs 659 Crore GENERICS: APIs & Generic Formulations

==> picture [241 x 159] intentionally omitted <==

Note: Revenue contribution as a % of Revenue from Operations

Note: *Q1FY25 Consolidated Revenue includes proceeds of Rs 1057 Cr on account of the strategic collaboration between Biocon Biologics & Eris Lifesciences.

1

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

Leadership Comments

BIOCON GROUP

“ Biocon has reported consolidated revenues of Rs 4,567 crore for Q1FY25, delivering a strong 30% YoY growth, with EBITDA growing 117% to Rs 1,755 crore and a Net Profit of Rs 660 crore. This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences. The underlying business performance of Biocon has been in line with our expectations. Post integration, the Biosimilars business has delivered a healthy performance with 11% like- for- like growth, as it consolidates business across global markets. This has helped offset the challenges of pricing pressures in the Generics segment and the difficult U.S. Biotech funding environment, which has impacted the growth trajectory of our Research Services business.

"The outlook for this fiscal remains positive as we anticipate stronger growth in H2FY25, with new product launches in the Biosimilars and Generics businesses, including Liraglutide for diabetes and obesity in the UK and other markets. Additionally, we expect improved business prospects for Syngene, supported by a resurgent biotech funding environment in the U.S."

--Kiran Mazumdar-Shaw, Executive Chairperson, Biocon and Biocon Biologics.

BIOCON GENERICS

“The Generics business continued to encounter pricing pressure and demand contraction, which impacted our first quarter’s performance of both APIs and Generic Formulations.

The business made progress on its Most of the World (MoW) expansion strategy with the signing of a partnership agreement with Handok in South Korea for the commercialization of Liraglutide. We also obtained our first injectable approval in the U.S. for Micafungin and secured some key customer contracts in the region.

“Looking ahead, our focus will be directed towards commercializing products for which we have received approvals, including Liraglutide, in the second half of this fiscal, as indicated previously. We will also continue to accelerate our cost improvement initiatives and expedite on-going capex projects.”

-- Siddharth Mittal, CEO & Managing Director, Biocon Limited.

BIOCON BIOLOGICS

“Having successfully integrated the acquired business last year, Biocon Biologics’ focus in FY25 now shifts to consolidation and setting up the business for growth. We began the fiscal year on a strong note with the business delivering year-on-year growth of 11% on a like-for-like basis. This growth was underpinned by an increase in market shares, tender wins in Europe and Emerging Markets and 15 new product launches.

This quarter YESAFILI™, our bAflibercept, became the 1[st] interchangeable biosimilar to be approved by the U.S. FDA. Our manufacturing facilities in Bengaluru, India and Johor, Malaysia received GMP certifications from leading regulatory agencies such as the European Medicines Agency (EMA) and Therapeutic Goods Administration (TGA), Australia. These milestones will serve as growth catalysts and allow us to expand our reach to millions of patients globally.”

-- Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited.

SYNGENE

2

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

“First quarter performance was broadly flat, in line with our expectations, reflecting the dip in funding for U.S. biotechs that has impacted our sector over the last two years. However, the value of U.S. biotech funding has seen a marked improvement in the first half of 2024. It will take a while for this funding to flow through into outsourcing activities and Syngene is in a strong position to capture a significant share of the upturn in biotech spending in the months ahead.”

-- Jonathan Hunt, CEO & Managing Director, Syngene International Limited.

FINANCIAL HIGHLIGHTS (CONSOLIDATED): Q1FY25 In Rs Crore

	Particulars	Q1FY25	Q1FY24	YoY (%)
	INCOME
	Generics	659	700	-6
	Biosimilars^	2,083	2,015	3^
	Research services	790	808	-2
	Inter-segment	(100)	(101)	-1
	Revenue from operations	3,433	3,423	0
	Other Income*	1,134	94	1,113
	Total Revenue	4,567	3,516	30
	Net R&D Expenses	228	315	-28
	Gross R&D Spend	228	324	-30
	EBITDA	1,755	808	117
	EBITDA Margins	38%	23%
	Core EBITDA**	903	936	-4
	Core EBITDA Margins	26%	28%
	PBT	1,146	184	524
	Net Profit (before Minority Interest )	862	149	479
	Net Profit	660	101	551

Figures above are rounded off to the nearest Crore; % based on absolute numbers.

Notes to financials above:

^Biosimilars Business revenue grew by 11% on a like- for- like basis.

* Q1FY25 includes proceeds of Rs 1057 Cr on account of the strategic collaboration between Biocon Biologics & Eris Lifesciences, and is reported under Other Income

**Core EBITDA excludes proceeds from the Eris transaction, R&D, Forex, Licensing income, Bicara fair value gain and derivative MTM loss/ gain

Financial Commentary: Q1FY25

Total Consolidated Revenue for Q1FY25 grew 30% year-on-year (YoY) to Rs 4,567 crore . Other Income includes proceeds of Rs 1,057 crore on account of the strategic collaboration between Biocon Biologics and Eris Lifesciences.

Core EBITDA at Rs 903 crore , represents core operating margins of 26%.

Net R&D investments for the quarter were Rs 228 crore , representing 9% of revenue ex-Syngene. EBITDA for the quarter stood at Rs 1,755 crore , representing an EBITDA margin of 38%. Profit Before Tax and exceptional items stood at Rs 1,114 crore.

Net Profit for the quarter, before exceptional items, stood at Rs 648 crore.

3

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

Net Profit (before minority interest) for the quarter was Rs 862 crore. Reported Net Profit for the quarter stood at Rs 660 crore.

CORPORATE HIGHLIGHTS

Management Updates

Biocon Biologics Limited

Joe Sian Chean Fei has been appointed as Vice President & Site Head, at Malaysia, to provide strategic leadership and direction to the site and oversee day-to-day operations across all functions. He brings with him over 25 years of experience in the Malaysian pharmaceutical industry and has a successful track record of managing pharmaceutical operations, strategic planning, and organizational development.

Business Highlights

GENERICS: APIs & Generic Formulations

• Q1FY25 Revenue at Rs 659 Crore, down 6% YoY

Business Performance

The Generics business reported a subdued first-quarter performance with demand challenges on its base products impacting revenues.

During the quarter, the Company obtained its first injectable approval in the U.S. – Micafungin for injection in 50mg and 100mg strengths. Micafungin is an antifungal medicine used to treat or prevent certain kinds of fungal or yeast infections.

The business also secured new customer contracts for Mycophenolic Sodium tablets and Liothyronine Sodium tablets in the U.S.

In line with the business’ regional expansion strategy, an exclusive licensing and supply agreement was entered into with Handok, a specialty pharmaceutical company in South Korea, for the commercialization of its vertically integrated drug product, Synthetic Liraglutide, used in the treatment of chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity.

Regulatory Inspections

The Company received a GMP certificate from TGA, Australia, for its Visakhapatnam API facility (Site 5). A regulatory inspection by ANVISA, Brazil, of its oral solid dosage facility in Bengaluru concluded with no major or critical observations. Two separate GMP inspections of the Company’s API facilities (Sites 5 & 6) at Visakhapatnam by the U.S. Food and Drug Administration (FDA) concluded with four and three observations, respectively, to which the Company has responded with a Corrective and Preventive Action (CAPA) plan. An Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) has been received for Site 5 and agency feedback for Site 6 is awaited.

BIOSIMILARS: Biocon Biologics

4

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

• Q1FY25 Revenue at Rs 2,083 Crore, Up 11% YoY on a like -for- like basis

• Served 5+ million patients (MAT June 2024 basis)[##]

##12-month moving annual patient population (July 2023 to June 2024)

Business Performance

Q1FY25

Biocon Biologics’ Q1FY25 revenue at Rs 2,083 crore reported a YoY growth of 11% on a like- forlike basis after adjusting* Q1FY24 revenue for Branded Formulations, India business.

Core EBITDA stood at Rs 614 crore , with Core EBITDA margin at 30%. EBITDA at Rs 474 crore reported healthy EBITDA margins of 23%* .

Notes: Q1FY25: Revenue and EBITDA does not include proceeds of Rs 1,057 core on account of the strategic collaboration and business transfer to Eris Lifesciences which is booked as Other Income. *Q1FY24 Revenue included Branded Formulations India sales which is not a part of Q1FY25 revenue.

North America[@]

Biocon Biologics is witnessing strong demand for its oncology portfolio, which is driving the growth in the U.S. market. The market share for Ogivri® (bTrastuzumab) grew significantly to 19% from 11% just a year ago. The share of Fulphila® (bPegfilgrastim) increased to 20% from 16% a year ago. Market access agreements for Fulphila® secured earlier came into effect this quarter, contributing to growth. The Company also signed new agreements for Fulphila®, one of which is with a regional health plan.

Biocon Biologics witnessed increased demand for its insulin products with additional market access agreements for bGlargine secured earlier, coming into effect in Q2FY25. The market share of unbranded bGlargine and Semglee® stood at 14%, including share from a large closed-door pharmacy network.

In case of Hulio ® (bAdalimumab), a new non-exclusive agreement with a national pharmacy benefit manager (PBM) became operational during the quarter. Additionally, Costco has added unbranded Adalimumab-fkjp Injection for its members in the Costco Members Prescription Program (CMPP), making it available for purchase for all 70 million Costco card holders in the U.S.

In Canada, there were market share improvements across most products over the comparable quarter last year. The share of Hulio® increased to 8% from 6% a year ago, and Kirsty ® (bAspart) secured a 3% market share.

During the quarter, the Company received U.S. Food and Drug Administration (FDA) approval for its first- to- file application for YESAFILI™ (Aflibercept-jbvf), an interchangeable biosimilar, which marks Biocon Biologics’ entry into the ophthalmology therapeutic area in the U.S. following approvals in Europe (Sep 2023) and the UK (Nov 2023) where it was the first bAflibercept to be approved.

Europe[&] and JANZ

The Company is focusing on expansion in Europe and establishing country-level infrastructure in several countries. It improved market shares for some of its products in several key markets and launched existing products in countries where its partner did not have a commercial presence previously.

5

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

Hulio® continues to hold leading markets share in France and Germany at ~11% and ~18%, respectively, leading to an overall market share of ~6% in Europe. During the quarter, the Company secured its first tenders for Abevmy® (bBevacizumab) and Ogivri® in the UK and a few new tenders in Italy, besides expanding its hospital reach in Portugal.

The Company continues to consolidate its business in Japan, Australia, and New Zealand and is exploring meaningful collaborations to drive growth.

@ North America: Market shares based on IQVIA June 2024 data.

& Europe: Market shares based on IQVIA Q1 CY2024 data.

Emerging Markets

Biocon Biologics reported a strong performance in the Emerging Markets on the back of higher sales of its key products bBevacizumab, rh-Insulin and bEtanercept in AFMET ; rh-Insulin and bTrastuzumab in APAC ; and Glargine, rh-Insulin and bEtanercept in LATAM . This is reflective of the strong sustainable foundation we have built, increase in the underlying demand and patient confidence in our high- quality products. During the quarter, the company expanded its reach by leveraging its new self-commercialization infrastructure and through 12 new launches, in several key markets.

The Company won several tenders for its key products and also secured 14 new regulatory approvals during the quarter, which will pave the way for future growth.

Regulatory Inspections

In June, Biocon Biologics received approval from the European Medicines Agency (EMA) to manufacture bBevacizumab at its world-class monoclonal antibodies Drug Substance facility in Bengaluru. Additionally, EMA renewed its Good Manufacturing Practice (GMP) Certificates of Compliance for the facilities in Bengaluru and Malaysia. In July the Company also received GMP certification from TGA, Australia for bTrastuzumab and bBevacizumab for its new monoclonal antibodies Drug Substance facility at Bengaluru.

Biocon Biologics underwent a U.S. FDA inspection of its manufacturing facilities in Bengaluru in July 2024. The 10-day-long combined cGMP and Pre-Licensing Inspection (PLI) included five monoclonal antibody products. The observations are procedural in nature and will be addressed through a comprehensive Corrective and Preventive Action (CAPA) plan, expeditiously. The Company does not expect the current supply of its products to be impacted.

Scientific Publications

Biocon Biologics continued to contribute to scientific excellence and biopharmaceutical research as evidenced by its recent scientific publications in reputed journals.

1. Use of Biosimilars in LMICs in GaBI Journal

This review article by Biocon offers insights into the challenges of biosimilar uptake and gives recommendations for faster and better access to biosimilars in emerging markets and, more broadly, LMICs. While acknowledging the fact that affordability remains a primary factor for purchasing

6

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

decisions of biologics, this paper offers additional criteria beyond price that may help the healthcare industry and regulatory agencies in LMICs select quality-assured biosimilars. Link: https://gabi-journal.net/increasing-adoption-of-quality-assured-biosimilars-to-address-accesschallenges-in-low-and-middle-income-countries.html

2. Aligning Environmental, Social, and Governance to Clinical Development: Moving Towards More Sustainable Clinical Trials in GaBI Journal

This article shows how aligning ESG principles with clinical development can lead to more sustainable clinical trials for biosimilars. The article also talks about developing tools capable of measuring the carbon footprint of biosimilar clinical trials and coming up with guidelines on how to reduce it. Link:https://gabi-journal.net/aligning-environmental-social-and-governance-to-clinicaldevelopment-moving-towards-more-sustainable-clinical-trials.html

3. Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials in Expert Opinion on

Biological Therapy

This review article talks about the potential move from one rapid-acting insulin analog to another, or their biosimilars, to aid better and faster decisions for diabetes management. This systematic literature review demonstrates that both aspart and lispro are comparable in safety and efficacy in patients with type 1 and type 2 diabetes and can be used interchangeably. Link: https://www.tandfonline.com/doi/full/10.1080/14712598.2024.2371046

RESEARCH SERVICES: Syngene

• Q1FY25 Revenue at Rs 790 Crore, down 2% YoY

Business Performance

The Dedicated Centers and Biologics Manufacturing Services reported steady growth. The repurposing of the biologics manufacturing facility acquired from Stelis Biopharma remains on schedule. Once operational, the facility will triple Syngene’s biologics manufacturing capacity. Though the Discovery Services revenue was hit by the dip in U.S. biotech funding, several pilot projects initiated this quarter will build a foundation for large-scale future collaborations in H2FY25. Development Services continued to attract repeat business from existing clients, reflecting high standards of service delivery .

Enclosed: Fact Sheet – with Financials as per IND-AS

About Biocon Limited:

Biocon Limited , publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the U.S., Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: @bioconlimited for company updates.

Biocon Biologics Limited, a subsidiary of Biocon Limited, is a unique, fully integrated, global biosimilars company committed to transforming healthcare and transforming lives. It is capitalizing

7

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

on its ‘lab to market’ capabilities to serve millions of patients across 120+ countries by enabling affordable access to high quality biosimilars. The Company is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.

Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many ‘firsts’ to its credit in the biosimilars industry. As part of its environmental, social and governance (ESG) commitment, it is advancing the health of patients, people, and the planet to achieve key UN Sustainable Development Goals (SDGs). Website: www.bioconbiologics.com; Follow us on Twitter : @BioconBiologics and LinkedIn : Biocon Biologics for company updates.

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company’s latest Environmental, Social, and Governance (ESG) report, visit https://esgreport.syngeneintl.com/

FOR MORE INFORMATION
MEDIA	INVESTORS
Biocon Group & Biocon Biologics Seema Ahuja Global Head of Communications & Corporate Brand +91 99723 17792  seema.ahuja@biocon.com	Biocon Saurabh Paliwal Head - Investor Relations +91 95383 80801  saurabh.paliwal@biocon.com
Biocon For Generics business Calvin Printer Head - Corporate Communications +91 70329 69537  calvin.printer@biocon.com

Earnings Call

The management of the Company will host an Earnings Call on August 9, 2024 at 09:00 hrs, over a Zoom Webinar, where the senior management will discuss the Company's performance and answer questions from participants. Details of the Zoom webinar is given below as well as on the Company website www.biocon.com under Investors >> Financial Calendar >> Earnings Call for the period ended June 30, 2024. Transcript of the conference call will be uploaded on the Company website in due course.

8

==> picture [80 x 30] intentionally omitted <==

==> picture [122 x 27] intentionally omitted <==

Zoom Webinar Details	Zoom Webinar Details
Date	August 9, 2024
Time	09:00 – 10:30 IST (UTC +05:30)
Join Zoom Webinar	Click here to attend earnings call

Forward-Looking Statements: Biocon

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our Directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

9

BIOCON GROUP

F A C T S H E E T

==> picture [62 x 10] intentionally omitted <==

----- Start of picture text -----

June - 2024
----- End of picture text -----

==> picture [491 x 509] intentionally omitted <==

----- Start of picture text -----

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Crores)
Particulars Q1 FY 25 Q1 FY 24 Variance %
INCOME
Generics 659 700 -6%
Biosimilars 2,083 2,015 3%
Novel Biologics - - 0%
Research services 790 808 -2%
Inter-segment (100) (101) -1%
Revenue from operations # 3,433 3,423 0%
Other income 1,134 94 1113%
TOTAL REVENUE 4,567 3,516 30%
EXPENDITURE
Material & Power costs 1,276 1,324 -4%
Staff costs 702 520 35%
Research & Development expenses 228 315 -28%
Other expenses 606 550 10%
Manufacturing, staff & other expenses 2,812 2,708 4%
EBITDA 1,755 808 117%
Interest & Finance charges 236 233 1%
Depreciation & Amortisation 405 358 13%
Share of loss / (profit) in JV / Associate, net - 33 -100%
PBT BEFORE EXCEPTIONAL ITEM 1,114 184 506%
Exceptional item 32 - -
PBT 1,146 184 524%
Taxes 273 35 684%
Taxes on exceptional item 11 - 100%
NET PROFIT BEFORE MINORITY INTEREST 862 149 479%
Minority interest 193 48 305%
Minority interest on exceptional item 10 - 100%
NET PROFIT FOR THE PERIOD 660 101 551%
EPS Rs. 5.5 0.8
NET PROFIT BEFORE EXCEPTIONAL ITEM 648 101 539%
Exceptional item, net of taxes 12 - 100%
NET PROFIT FOR THE PERIOD 660 101 551%
# Licensing Income 6 167
Gross Research & Development expenses 228 324
----- End of picture text -----

==> picture [458 x 494] intentionally omitted <==

----- Start of picture text -----

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT (Rs. Crores)
Particulars Q1 FY 25 Q4 FY 24 Variance %
INCOME
Generics 659 719 -8%
Biosimilars 2,083 2,358 -12%
Research services 790 917 -14%
Inter-segment (100) (76) 31%
Revenue from operations # 3,433 3,917 -12%
Other income 1,134 49 2239%
TOTAL REVENUE 4,567 3,966 15%
EXPENDITURE
Material & Power costs 1,276 1,417 -10%
Staff costs 702 532 32%
Research & Development expenses 228 246 -7%
Other expenses 606 806 -25%
Manufacturing, staff & other expenses 2,812 3,001 -6%
EBITDA 1,755 964 82%
Interest & Finance charges 236 227 4%
Depreciation & Amortisation 405 407 0%
Share of loss / (profit) in JV / Associate, net - 3 -100%
PBT BEFORE EXCEPTIONAL ITEM 1,114 328 240%
Exceptional item, Net 32 (9) -100%
PBT 1,146 319 259%
Taxes 273 98 180%
Taxes on exceptional item 11 (2) -820%
NET PROFIT BEFORE MINORITY INTEREST 862 223 287%
Minority interest 193 87 121%
Minority interest on exceptional item 10 - -
NET PROFIT FOR THE PERIOD 660 136 386%
EPS Rs. 5.5 1.1
NET PROFIT BEFORE EXCEPTIONAL ITEM 648 144 351%
Exceptional item 12 (8)
NET PROFIT FOR THE PERIOD 660 136 386%
# Licensing Income 6 15
Gross Research & Development expenses 228 228
----- End of picture text -----

==> picture [432 x 717] intentionally omitted <==

----- Start of picture text -----

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET
(Rs Crores)
Particulars Jun 30, 2024 Mar 31, 2024
ASSETS
Non-current assets
(a) Property, plant and equipment 7,368 7,418
(b) Capital work-in-progress 4,168 3,985
(c) Right-of-use assets 597 575
(d) Goodwill 16,378 16,372
(e) Other intangible assets 6,136 6,279
(f) Intangible assets under development 4,101 4,008
(g) Financial assets
Investments 660 684
Derivative assets 256 266
Other financial assets 157 147
(i) Income tax asset, net 434 413
(j) Deferred tax asset, net 282 317
(k) Other non-current assets 480 428
Non-current assets 41,017 40,892
Current assets
(a) Inventories 5,037 4,944
(b) Financial assets
Investments 814 316
Trade receivables 5,635 6,231
Cash and cash equivalents 1,357 1,234
Other bank balances 562 1,025
Derivative assets 179 138
Other financial assets 275 577
(c) Other current assets 795 715
Current assets 14,654 15,180
TOTAL - ASSETS 55,671 56,072
EQUITY AND LIABILITIES
Equity
(a) Equity share capital 600 600
(b) Other equity 19,898 19,183
Equity attributable to owners of the Company 20,498 19,783
Non-controlling interests 5,715 5,491
Total Equity 26,213 25,274
Non-current liabilities
(a) Financial liabilities
Borrowings 12,454 12,932
Lease liabilities 472 492
Other financial liabilities 1,115 1,073
(b) Other non-current liabilities 346 311
(c) Provisions 235 238
(d) Deferred tax liability, net 397 392
Non-current liabilities 15,019 15,438
Current liabilities
(a) Financial liabilities
Borrowings 3,362 2,797
Lease liabilities 99 55
Trade payables 5,661 6,272
Derivative liabilities - 1
Other financial liabilities 4,130 5,001
(b) Other current liabilities 701 777
(c) Provisions 197 180
(d) Income tax liability, net 289 277
Current liabilities 14,439 15,360
TOTAL - EQUITY AND LIABILITIES 55,671 56,072
----- End of picture text -----